

1 **Day 3 parasitemia and *Plasmodium falciparum* Kelch 13 mutations among uncomplicated**
2 **malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda**

3 Martin Kamilo Angwe^{1,2,3*}, Norah Mwebaza¹, Sam Lubwama Nsobya⁴, Patrick Vudriko²,
4 Savior Dralabu², Denis Omali^{1,5}, Maria Agnes Tumwebaze², Moses Ocan¹

5

6 ¹Department of Pharmacology and Therapeutics, College of Health Science, Makerere
7 University.

8 ²Research Center for Tropical Diseases and Vector Control, Department of Pharmacy, Clinical
9 and Comparative Medicine, School of Veterinary Medicine and Animal Resources, College of
10 Veterinary Medicine, Animal Resources and Biosecurity, Makerere University.

11 ³Department of Biomolecular Resources and Biolab Sciences, School of Biosecurity,
12 Biotechnical and Laboratory Science, College of Veterinary Medicine, Animal Resources and
13 Biosecurity Makerere University

14 ⁴Infectious Diseases Research Collaboration, Makerere University.

15 ⁵Infectious Disease Institute, Makerere University.

16

17 *Corresponding author

18 Email: martin.angwe@mak.ac.ug

19 **Abstract**

20 Artemisinin resistance threatens malaria control and elimination efforts globally. Recent
21 studies have reported the emergence of *Plasmodium falciparum* parasites tolerant to
22 artemisinin agents in sub-Saharan Africa, including Uganda. The current study assessed the
23 day 3 parasite clearance and its correlation with *P. falciparum* *K13* propeller gene (*pfkelch13*)
24 mutations in *P. falciparum* parasites isolated from patients with uncomplicated malaria under
25 artemether-lumefantrine (AL) treatment. This study enrolled 100 *P. falciparum*-positive
26 patients to whom AL was prescribed between 09/September/2022 and 06/November/2022.
27 Blood samples were collected in EDTA tubes before treatment initiation (day 0) and on day 3.
28 Parasitemia was assessed by microscopy from blood smears and quantitative polymerase chain
29 reaction (qPCR) from the DNA extracted. The day 0 parasite *K13* gene was sequenced using
30 Sanger sequencing. Sequence data were analysed using MEGA *version* 11 software. The data
31 were analysed using STATA *version* 15, and the Mann–Whitney U test was used to compare
32 PCR parasite clearance on day 3 using the comparative CT value method and *pfkelch13*
33 mutations.

34 The prevalence of day 3 parasitaemia was 24% (24/100) by microscopy and 63% (63/100) by
35 qPCR from the AL-treated patients. *P. falciparum* *K13*-propeller gene polymorphism was
36 detected in 18.8% (15/80) of the day 0 DNA samples. The *K13* mutations found were C469Y,
37 12.5% (10/80); A675V, 2.5% (2/80); A569S, 1.25%, (1/80), A578S, 1.25%, (1/80) and; F491S,
38 1.25%, (1/80) a new allele not reported anywhere. The C469Y mutation, compared to the wild-
39 type, was associated with delayed parasite clearance $p=0.0278$, Hodges-Lehmann estimation
40 3.2108 on the log scale, (95%CI 1.7076, 4.4730).

41 There was a high prevalence of day 3 *P. falciparum* among malaria patients treated using
42 artemether-lumefantrine. We conclude that the *K13* mutation associated with artemisinin

43 resistance by *P. falciparum* is present in Adjumani district, Uganda. This necessitates regular
44 surveillance of the effectiveness and efficacy of artemether-lumefantrine in the country.

45 *Keywords: Artemether-lumefantrine, Day 3 parasitaemia, Artemisinin resistance, K13*
46 *mutation, Plasmodium falciparum.*

47 **Introduction**

48 Malaria continues to pose a substantial global health challenge, with sub-Saharan Africa (SSA)
49 bearing the highest burden of the disease's impact. In 2022, the World Health Organization
50 (WHO) reported 249 million malaria cases worldwide, an increase of at least 5 million cases
51 compared to the previous year, with the WHO African region accounting for 94% of the cases
52 (1,2). Uganda contributes at least 5% of the worldwide malaria cases, most of which occur in
53 rural areas, especially in Northern and Eastern Uganda. There have been extensive control and
54 prevention interventions, such as the distribution of insecticide-treated bed nets (ITNs)
55 covering at least 82% of households in Uganda, indoor residual spraying (IRS) in some regions
56 being scaled up, and antimalarial medications. Despite these interventions, the area has
57 witnessed stagnation in malaria elimination efforts and an increase in malaria cases in Northern
58 Uganda, highlighting the persistent challenge of malaria, especially in resource-limited settings
59 (3).

60 The current malaria treatment approach for uncomplicated *Plasmodium falciparum* infection
61 involves using artemisinin-based combination therapies (ACTs). Uganda adopted artemether-
62 lumefantrine (AL) as a first-line therapy for uncomplicated *P. falciparum* malaria, which has
63 been crucial in reducing malaria mortalities for almost two decades (1,4–6). These therapies
64 combine the short-acting artemisinin derivative (artemether) with another long-acting
65 antimalarial drug (lumefantrine), enhancing efficacy and reducing the risk of resistance
66 development. In addition to case management by the ACTs, control measures such as ITNs,
67 IRS, and malaria chemoprevention have been integral in reducing malaria transmission (7–12).
68 Despite these efforts, several challenges persist in the fight against malaria. Inadequate supply
69 of antimalarial medicines, especially in remote areas, often results in stockouts of ACTs, the
70 cornerstone of malaria treatment (13). Moreover, the proliferation of substandard antimalarial

71 agents and self-medication pose a significant public health risk, undermining treatment
72 effectiveness and contributing to artemisinin resistance development (14,15). Artemisinin
73 resistance, characterised by *Pfkelch13* (*K13*) gene mutations (16) and delayed parasite
74 clearance, has emerged as a serious concern, and molecular markers of artemisinin resistance
75 have been identified in many SSA countries (17,18). Recent studies in Uganda reported the
76 emergence of artemisinin resistance in the Eastern and Northern regions (19–21), a threat that
77 is becoming evident to the effectiveness of artemisinin combination therapy.

78 The widespread development of artemisinin resistance could reverse the gains made in malaria
79 control and elimination, potentially leading to an increase in malaria morbidity and mortality.
80 This may lead to a similar catastrophic event previously observed when chloroquine was
81 withdrawn from malaria treatment due to widespread resistance (22,23). In Uganda, where
82 healthcare systems are often overburdened with limited access to quality healthcare (24,25),
83 the spread of artemisinin resistance could undermine decades of progress and investment in
84 malaria control, and this could be worsen by the lack of effective alternatives to artemisinin
85 antimalarial agents in malaria treatment.

86 This study assessed the prevalence of day 3 *P. falciparum* in patients with uncomplicated
87 malaria treated with AL and the prevalence of *K13*-propeller gene mutations associated with
88 artemisinin resistance. The study's findings provide context-specific evidence on artemisinin
89 resistance among *P. falciparum* parasites in patients treated using artemether-lumefantrine in
90 the West Nile region, Uganda.

91 **Materials and Methods**

92 **Ethical statement.**

93 The protocol was reviewed, and ethical approval was obtained from the School of Biomedical
94 Sciences Research and Ethics Committee at the College of Health Sciences, Makerere
95 University (SBS-2022-157). Administrative clearance was obtained from Adjumani district
96 authorities. Written informed consent was obtained from all participants before data collection,
97 parental consent was obtained from participants aged 5-7 years, assent and parental consent
98 were obtained from participants aged 8-17 years, and participants 18 years old and above
99 consented to the study.

100 **Study area**

101 The study was conducted in the Adjumani district located in the West Nile region, northwest
102 of Uganda. The region neighbours the Democratic Republic of Congo and South Sudan. The
103 district is among the highest malaria endemic districts in the country, with malaria transmission
104 throughout the year and a prevalence reported above 50% by microscopy during the country's
105 malaria indicator survey (26).

106 **Study design**

107 This was a prospective longitudinal study which recruited malaria patients between
108 09/September/2022 and 06/November/2022 receiving artemether-lumefantrine (AL) 20 mg
109 artemether/120 mg lumefantrine tablets, 3-day six-dose regimen prescribed according to
110 patient weight for treatment of uncomplicated malaria at Adjumani District Hospital. Blood
111 samples were collected from the patient on day 0 (before drug intake) and day 3 (after
112 treatment). The study enrolled 100 purposively selected uncomplicated malaria patients aged
113 five years and above with confirmed *P. falciparum* infection. A study purpose non-validated

114 questionnaire was used to collect information on the socio-demographic characteristics of the
115 patients, including age, gender, and previous history of malaria treatment. The study collected
116 both patient socio-demographic and laboratory data. *Plasmodium falciparum* parasite
117 infections among symptomatic malaria patients were determined using microscopy and qPCR
118 from the College of Veterinary Medicine Animal Resources and Biosecurity,
119 Pharmacology/Research Center for Tropical Diseases and Vector Control, and Central
120 Diagnostic Laboratory.

121 **Blood sample collection.**

122 Venous blood (2-3ml) was collected in an EDTA tube. Two blood samples were collected from
123 each patient; the first was on day 0, before initiation of treatment, and the second was collected
124 on day 3, after completion of artemether-lumefantrine therapy.

125 **Microscopy**

126 On days 0 and 3, thick and thin smears were prepared for detection and speciation of
127 *Plasmodium falciparum* infection, respectively. The blood smears were stained with 10%
128 Giemsa stain for 30 minutes, then examined using an Olympus microscope under 100X
129 magnification with oil immersion to identify the parasite and determine the parasite density.
130 Two independent microscopists/laboratory technologists examined the slides for *P. falciparum*
131 confirmation and enumeration.

132 **DNA extraction**

133 The parasite DNA was extracted using a Qiagen DNA mini kit (QIAamp DNA Blood Mini
134 Kit-250, Germany), following the manufacturer's instructions. Elution was performed in 50 μ L
135 elution buffer, and the DNA concentration was determined (25-40 ng/ μ l) using NanoDrop
136 (NanoDrope Lite Plus, thermo scientific) before PCR amplification.

137 ***Plasmodium falciparum* qPCR**

138 Quantitative PCR (qPCR) was performed using a real-time PCR system (QuantStudio™5) to
139 detect and quantify the *Plasmodium falciparum* in duplicate. Primers and probes were based
140 on the 18S rRNA sequence (27) synthesised from Inqaba Biotec Laboratory, South Africa. The
141 amplification followed a method in a previous study (28). The CT values were recorded and
142 used to calculate parasite clearance through fold change, $2^{-\Delta\Delta CT}$ by a comparative CT value
143 method (29). The method considered two data points of CT values at day 0 and day 3 for
144 individuals that remained positive on day 3.

145 Specific primers were used for the qPCR (Table 1); the probe was labelled with 5'FAM (6-
146 carboxyfluorescein) and BHQ-1™ (Black Hole Quencher) as the reporter and quencher,
147 respectively. 20 µl reaction volume was prepared, composed of 0.8 µl of each forward and
148 reverse primer, 10 µl of qPCR master mix (Luna Universal Probe qPCR Master Mix NEB,
149 New England BioLabs Inc), 0.4 µl of the probes, 20 ng of the DNA template and nuclease-
150 free water (variable). The PCR conditions involved one cycle at 94°C for 5 min of initial
151 denaturation, followed by 40 cycles of denaturation at 94°C for 30 s, annealing at 54°C for 90
152 s and extension at 68°C for 90 s, and a final extension at 68°C for 90 s.

153 ***P. falciparum* K13 allele**

154 Conventional nested PCR was performed (SimpliAmp Thermal Cycler, applied biosystem) to
155 amplify approximately 800 bp fragment that extends from nucleotides position 1329-to-2178
156 (codons 445-to-727) within the propeller domain of the *K13* gene using the specific primers
157 (16) Table 1.

158 Table 1: Primer sequences used for nested PCR and qPCR

PCR	Primers	Sequence
Nested PCR	K131/K13_PCR-F	5'CGGAGTGACCAAATCTGGGA-3'
	K134/K13_PCR_R	5'-GGGAATCTGGTGGTAACAGC-3'
	K132/K13_N1_F	5'GCCAAGCTGCCATTCATTTG-3'
	K133/K13_N1_R	5'-GCCTTGTTGAAAGAAGCAGA-3'
qPCR	Forward	5'-GCTCTTTCTTGATTTCTTGGATG-3
	Reverse	5'-AGCAGGTTAAGATCTCGTTCG-3'.
	Probe	5'-ATGGCCGTTTTTAGTTCGTG-3'

159

160 ***P. falciparum* K13 gene amplification**

161 The first round PCR was performed in a 25 µl reaction volume of 12.5 µl OneTaq 2X Master
 162 Mix (NEB, New England BioLabs Inc), 1 µl of each forward and reverse primer and 2.5 ng
 163 of the DNA template and nuclease-free water (variable). The PCR was run with the following
 164 conditions: 94°C for 5 m initial denaturation, 40 cycles at 94°C for 30 s, annealing at 54°C for
 165 90 s, and extension at 68°C for 90 s. The final extension was performed at 68°C for 10 minutes,
 166 then kept at 4°C, which was set to infinite. The amplicon from the first round of PCR was used
 167 as a template for the second round. This was run in a 25 µL reaction mixture volume; it involved
 168 the same master mix preparation as the first run, but the second primer sets were used with 1
 169 µl of the first PCR product/amplicon. The PCR product was visualised using gel
 170 electrophoresis run at 100 V for 30 minutes in 1.5% agarose stained with 0.05 µg/mL Acridine
 171 orange (SafeView Classic).

172 **Amplicon preparation and cleaning**

173 The nested PCR products were cleaned using ExoSAP. The Exo/SAP master mix was prepared
174 by adding 50 µL of exonuclease I (Catalogue No. NEB M0293) 20 U/µl and 200 µl of shrimp
175 alkaline phosphatase (Catalogue No. NEB M0371) 1 U/µl to a 0.6 ml microcentrifuge tube.
176 Then, 2.5 µl of the ExoSAP mixture was mixed with 10 µL of the amplicon/PCR product and
177 incubated at 37°C for 15 min; the reaction was stopped by heating the mixture at 80°C for 15
178 min.

179 ***Plasmodium falciparum* K13 Sequencing**

180 The nested PCR products were sequenced using the Nimagen BrilliantDye™ Terminator Cycle
181 Sequencing kit V3.1, BRD3-100/1000, according to the manufacturer's instructions at the
182 Inqaba Biotec laboratory in South Africa, a commercial sequencing company. The labelled
183 product was then cleaned with a ZR-96 DNA sequencing clean-up Kit (Catalogue No. D4053).
184 The cleaned product was injected into an Applied Biosystems ABI 3730XL Genetic Analyser
185 with a 50 cm array using POP7. Sequence chromatogram analysis was performed using
186 FinchTV analysis software.

187 **Data management and analysis**

188 The *K13* sequence qualities were assessed, and then BLAST against the NCBI database to
189 confirm the identity of the gene sequence. After exporting the sequence into the Bioedit
190 sequence alignment editor, manual editing was performed, and the sequence was exported into
191 MEGA11 software for polymorphism detection using the sequence *PF3D7_1343700* from the
192 NCBI database as the reference sequence. Sequence alignment was performed using the
193 ClustalW algorithm, and a phylogenetic tree was drawn using MEGA11 Tree Explorer to
194 identify divergence in the *P. falciparum* *K13* genes and identify the mutations. Data were
195 entered in Excel and analysed in STATA version 17; CT value fold change from the qPCR data

196 was log-transformed before correlation. The relationship between the CT value fold change
197 related to parasite clearance and *K13* mutation was determined through a nonparametric test
198 (Mann-Whitney U test) with a 95% confidence interval and level of significance set at $p<0.05$.

199 **Results**

200 **Characteristics of the study participants**

201 The study included 100 symptomatic uncomplicated malaria patients, of which the majority,
202 65% (65/100), were females. The mean age of the study participants was 17 ± 10 years, ranging
203 from 5 to 46 years. Parasitemia/ μl geometric mean by microscopy was 3868, IQR 11104 for
204 all patients.

205 **Prevalence of *P. falciparum* on day three after AL treatment**

206 *P. falciparum* parasites persisted in 24% (24/100; 95%CI: 16-33) of the participants screened
207 using microscopy, whereas by PCR, the parasites were found in over half, 63% (63/100;
208 95%CI: 53-72) on day 3 following artemether-lumefantrine treatment (Table 2).

209

210 **Table 2: Day 3 *P. falciparum* positivity distribution among the different age groups.**

211

Characteristics	Microscopy and PCR positive, day 0 (N=100)	Day 3 positivity	
		Microscopy, n (%)	PCR n (%)
Age			
5-12	35	10 (28.57)	23 (65.71)
13-18	37	9 (24.32)	24 (64.86)
19 and above	28	5 (17.86)	16 (57.14)
Sex			
Male n=35	35	7 (20.00)	22 (62.86)
Female n=65	65	17 (26.15)	41 (63.08)
Total Participants	100	24 (24.00)	63 (63.00)

212 N=number of participants; n=number of participants who remained positive on day 3

213

214 **Prevalence of *Pfkelch13* Single nucleotide polymorphism (SNPs)**

215 A total of 80 samples (amplicons) out of the 100 were successfully sequenced for *K13* Single
216 Nucleotide Polymorphism (SNP) identification. Of the 80 sequenced samples, 24/80 were the
217 day 3 microscopy positive, and 58/80 were day 3 PCR positive samples; the 20/100
218 unsequenced samples contain 5/20 day 3 qPCR positive samples, but all microscopy negative
219 (20/20). *K13* SNPs were detected in 18.8% (15/80; 95%CI: 11.25-27.5) of the *P. falciparum*
220 parasite samples sequenced (Table 3). All the *K13* SNPs were nonsynonymous mutations. The
221 most prevalent nonsynonymous *K13* SNP was C469Y, at 12.5% (10/80; 95%CI: 6.25-20).
222 Other *K13* SNPs in the *P. falciparum* parasites were A675V (2.25%, 2/80; 95%CI: 0.0-6.25),
223 A569S (1.25%, 1/80; 95%CI:0.0-3.75) and A578S (1.25%, 1/80; 95%CI: 0.0-3.75). One
224 mutation not previously reported was detected in one sample where amino acid F was
225 substituted by S at codon 491 in the *K13* propeller domain, involving a nucleotide change from
226 T to C at position 1472.

227 **Table 3: Prevalence of *K13* single-nucleotide polymorphisms in *P. falciparum* parasites among patients in Adjumani District.**

228

Mutations	Wild-type amino acid	Mutant amino acid	Codon position	Wild-type nucleotide	Mutant nucleotide	Mutation type	Nucleotide position	Prevalence (n=80)
C469Y ^{ab}	Cysteine	Tyrosine	469	G	A	NS	1406	12.50% (n=10)
A675V ^{ab}	Alanine	Valine	675	C	T	NS	2024	2.50% (n=2)
A569S ^a	Alanine	Serine	569	G	T	NS	1705	1.25% (n=1)
A578S ^a	Alanine	Serine	578	G	T	NS	1732	1.25% (n=1)
F491S	Phenylalanine	Serine	491	T	C	NS	1491	1.25% (n=1)

229 NS=non synonymous mutation; n=number of samples sequenced; ^aPreviously reported *K13* allele, ^{ab}Candidate for artemisinin resistance

230 **Relationship between day 3 *P. falciparum* clearance and *Pfkelch13* Single nucleotide**
231 **polymorphism.**

232 Eight (8/10) patients with parasites with C469Y and one (1/1) patient with the A578S *P.*
233 *falciparum* *K13* mutation remained positive on day three by PCR. By microscopy, 5/10 patients
234 with *P.falciparum* having C469Y and 1/1 having A578S remained positive on day 3 (Table 4).
235 A comparison of the parasite clearance between the wild-type, median parasite fold reduction
236 522, 7043 (median, IQR) and mutated *K13* parasites showed significantly low parasite
237 clearance in C469Y, median fold reduction 14, 792 (Median, IQR) and A578S, fold reduction
238 1.6. Among the day 3 qPCR-positive *P. falciparum* patients, those with the C469Y mutated *P.*
239 *falciparum* demonstrated low parasite clearance compared to the wild-type $p=0.0278$, Hodges-
240 Lehmann estimation 3.2108 on the log scale (95% CI 1.7076, 4.4730). Parasitemia/ μ l geometric
241 mean for patients with wild-type *P. falciparum* 65/80 was 3795, IQR 10589, while that for the
242 patients with C469Y *P. falciparum* (10/80) was 3373, IQR 26099 for the sequenced samples.

243 Table 4: Day 3 positivity and CT value fold change in the K13 alleles from the parasites sequenced

K13 allele	CT value fold change/Parasite			
	Initial parasitemia Geo mean (IQR)	Day 3 positivity Microscopy PCR		clearance Median (IQR)
Wild-type, n=65	3794.954 (10588.5)	18	49	522 (7043)
C469Y, n=10	3373.35 (26099.5)	5	8	14 (792)
A675V, n=2	1578, 25651	0	0	-
A569S, n=1	27651	0	0	-
A578S, n=1	1782	1	1	1.6
F491S, n=1	8544	0	0	-

244

245 **Discussion**

246 Artemether-lumefantrine (AL), the first-line treatment for uncomplicated malaria in Uganda,
247 at the current standard fixed weight-based dose regimen, has been pivotal in reducing malaria-
248 related morbidity and mortality. However, emerging *P. falciparum* *K13* mutations associated
249 with reduced *P. falciparum* susceptibility to AL threaten malaria control and elimination efforts
250 in sub-Saharan Africa. Reduced susceptibility to AL that may be characterised by the
251 persistence of the parasite on day 3 could be associated with partial artemisinin resistance.

252 Our study reports that, on day 3, there was a prevalence of 24% *P. falciparum* by microscopy
253 among the patients treated with AL in Adjumani district, Northern Uganda. This could indicate
254 the emergence of partial artemisinin resistance. We observed a high prevalence of *P.*
255 *falciparum* parasites by microscopy, 24% and quantitative polymerase chain reaction (qPCR),
256 63%, after three days of AL treatment. This observation aligns with previous studies that have
257 reported similar persistence of parasites beyond the standard three-day treatment period in
258 Africa and elsewhere (30–33). Equally, our qPCR results indicated a prevalence of 63%,
259 consistent with a study by Tadele et al. (28) that reported a 60% PCR prevalence of day three
260 *P. falciparum* parasites among patients treated with AL, which may not be sufficient to indicate
261 the development of partial artemisinin resistance. However, the 24% prevalence by microscopy
262 could be a pointer to the potential emergence of partial *P. falciparum* resistance against AL,
263 the current cornerstone of malaria treatment. WHO advises that a day-three parasitemia in
264 patients on ACT treatment calls for routine monitoring to identify suspected artemisinin partial
265 resistance in *P. falciparum* (34).

266 The persistence of *P. falciparum* parasites on day 3 raises a concern regarding the current
267 effectiveness of artemether and the efficacy of the AL regimen. Our study found a 24%
268 microscopy positivity for *P. falciparum* on day three, which could indicate a possible

269 emergence of partial artemisinin resistance (35,36). A similar finding on the persistence of *P.*
270 *falciparum* has been reported previously in AL-treated malaria patients in Uganda (30,37–39).
271 Whether this is attributed to the development of resistance, especially the *K13* mutation, or lack
272 of adherence to AL has not been fully established. However, a previous study in Uganda has
273 demonstrated moderate to high adherence to AL in treating uncomplicated malaria, whether
274 taken under supervision or not (40). Day 3 positivity and residual *P. falciparum* are likely to
275 cause an increase in malaria recurrence and transmission to female *Anopheles* mosquitoes (41),
276 driving infection to people and jeopardising the gain in malaria control.

277 The study identified nonsynonymous mutations at codons 469, 675, 569, 578 and 491 of the
278 *K13* propeller gene. This mutation pattern is consistent with recent findings in Uganda
279 (20,39,42–44). The codons 469 and 675 mutations have been associated with artemisinin
280 resistance in northern Uganda (19,21). This is consistent with our finding that most patients
281 with C469Y-mutated *P. falciparum* had parasites that persisted after three days of AL
282 treatment. Among the *K13* mutations identified, patients carrying parasites with C469Y (5/10)
283 and A578S (1/1) mutations remained microscopy-positive on day 3; similarly, qPCR results
284 showed high day 3 positivity (8/10) for the C469Y. Unlike a study by Stoke et al. (45) that did
285 not link the C469Y mutation with parasite resistance or delay in parasite clearance, in this
286 study, C469Y was associated with low parasite fold reduction 14, 792 (median, IQR),
287 compared to the wild-type, an indication of reduced *P. falciparum* clearance. This is consistent
288 with the findings of Balikagala et al. and Tumwebaze et al. (19,21) that demonstrated delayed
289 parasite clearance and resistance. A similar study in Pakistan reported a high association
290 between C469Y and artemisinin resistance (46). Among the patients with *P. falciparum* that
291 remained positive on day 3, we identified one patient (1/1) with A578S mutated parasite having
292 a low parasite fold reduction of 1.6. The A578S mutation has been sporadically reported in
293 sub-Saharan African countries (20,47–49), and a study in Uganda reported some association

294 between A578S and slow parasite clearance (50), contrary to studies elsewhere that could not
295 associate it with artemisinin resistance (51,52).

296 The prevalence of mutation at codon 675 in the malaria patients was 2.5%, and none of the
297 patients with parasites having the A675V mutation remained *P. falciparum* positive on day 3.
298 Although the A675V mutation was previously associated with resistance in Northern Uganda
299 (19), our current study could not link the few to the persistence of *P. falciparum* on day 3,
300 possibly due to the low prevalence and likelihood of chance finding that they are not positive
301 on day 3. Although the A675V mutation is a candidate mutation for artemisinin resistance, a
302 study by Tumwebaze et al. and Stoke et al. (21,45) reported high parasite clearance among
303 parasites with the A675V mutations. We also identified a mutation at codon position 491,
304 which had previously not been identified anywhere. This finding shows the existence of a
305 reservoir for *K13* propeller gene polymorphisms, not only in Uganda but also globally in
306 malaria-endemic places (53,54). The diversity of *K13* propeller gene mutations across regions
307 further emphasises the need for continued surveillance and research to understand their
308 implications in artemisinin resistance.

309 Our study had some limitations. Firstly, parasites detected on day 3 were not confirmed
310 whether they were the same parasite on day 0 or a newly acquired infection. Secondly, we did
311 not confirm adherence to treatment among malaria patients who participated in the study.
312 Third, the parasite load on day 0 was not the same across all the patients; low and high *P.*
313 *falciparum* infections were all considered; the study considered *P. falciparum* positive patients
314 with no specific parasite load and as long as they were prescribed AL. Fourth, the study used
315 two data points of day 0 and day 3 to determine the parasite clearance through fold changes;
316 this makes the data less likely to precisely establish the linear correlation of the parasite
317 clearance slope and unable to capture the fold change pattern of those who are negative on day

318 3. Lastly, the clinical outcome of the participants was not evaluated according to the WHO 28-
319 day recommendation for an efficacy study. However, the limitations were unlikely to
320 significantly affect the study's outcome in determining artemisinin effectiveness and
321 identifying markers of artemisinin resistance. Future studies should consider using multiple
322 data points when using the CT value method to assess parasite clearance in effectiveness and
323 efficacy studies of artemisinin.

324 **Conclusion**

325 The day 3 prevalence of 24% *P. falciparum* by microscopy in the AL-treated patients could
326 indicate the presence of partial resistance to artemisinin. There is an increase in the prevalence
327 of K13 mutation associated with resistance, especially the C469Y, which is associated with a
328 low-fold change in parasite reduction. There is a need to re-evaluate the effectiveness of
329 artemisinin agents in malaria treatment and ensure continuous monitoring of their efficacy in
330 Uganda.

331 **Acknowledgement**

332 We acknowledge the research participants from Adjumani Hospital, the staff of Adjumani
333 Hospital: Mr Amosu Emmanuel (Laboratory Technologist), Mr Iranya Vincent (Clinical
334 Officer), Mr Amaruma Allan Levi (Clinical Officer), and Mr Anyanzo Ben (Community
335 Health Worker). Colleagues at Pharmacology/Research Center for Tropical Disease and Vector
336 Control (RTC) laboratory and Central Diagnostic Laboratory.

337 **Funding**

338 This study was supported by funding through the EDCTP2 programme supported by the
339 European Union (TMA2019CDF-2662-Pfkelch13 emergence) and Fogarty International
340 Center of the National Institute of Health under award number 1R25TW011213. The content

341 is solely the responsibility of the authors and does not necessarily represent the official view
342 of the EDCTP and the National Institute of Health.

343 **Authors Contributions**

344 Conceived and designed the study: MKA MO NM SLN. Performed the experiments: MKA DS
345 MAT. Analysed the data: MKA MO NM. Contributed reagents/materials/analysis tools: MKA
346 MO VP. Initial drafting of manuscript: MKA. Contributed to the final writing of the
347 manuscript: MKA MO NM SLN DS OD VP MAT.

348

349 **References**

- 350 1. Health Organization W. World malaria report 2022 [Internet]. Available from:
351 <https://www.who.int/teams/global-malaria-programme>
- 352 2. Health Organization W. World malaria report 2022 [Internet]. 2023. Available from:
353 <https://www.wipo.int/amc/en/mediation/>
- 354 3. The Republic of Uganda Ministry of Health. Uganda Malaria Indicator Survey 2018-
355 2019. 2020.
- 356 4. Bukirwa H, Yeka A, Kanya MR, Talisuna A, Banek K, Bakyaite N, et al. Artemisinin
357 Combination Therapies for Treatment of Uncomplicated Malaria in Uganda. 2006;
358 Available from: www.plosclinicaltrials.org
- 359 5. Sarah G Staedke, Arthur Mpimbaza, Moses R Kanya, Bridget K Nzarubara, Grant
360 Dorsey, Philip J Rosenthal. Combination treatments for uncomplicated falciparum
361 malaria in Kampala, Uganda: randomised clinical trial [Internet]. Available from:
362 www.thelancet.com

- 363 6. Organization WH. Guidelines for the treatment of malaria. World Health Organization;
364 2015.
- 365 7. Nankabirwa JI, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, et al. Malaria
366 transmission, infection, and disease following sustained indoor residual spraying of
367 insecticide in Tororo, Uganda. *American Journal of Tropical Medicine and Hygiene*.
368 2020 Oct 1;103(4):1525–33.
- 369 8. Oguttu DW, Matovu JKB, Okumu DC, Ario AR, Okullo AE, Opigo J, et al. Rapid
370 reduction of malaria following introduction of vector control interventions in Tororo
371 District, Uganda: a descriptive study. *Malar J*. 2017;16(1):1–8.
- 372 9. Katureebe A, Zinszer K, Arinaitwe E, Rek J, Kakande E, Charland K, et al. Measures
373 of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor
374 Residual Spraying at Three Sites in Uganda: A Prospective Observational Study. *PLoS*
375 *Med*. 2016 Nov 1;13(11).
- 376 10. Kwambai TK, Dhabangi A, Idro R, Opoka R, Watson V, Kariuki S, et al. Malaria
377 Chemoprevention in the Postdischarge Management of Severe Anemia. *New England*
378 *Journal of Medicine*. 2020 Dec 3;383(23):2242–54.
- 379 11. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, et
380 al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of
381 malaria parasites isolated from Ugandan children. *Antimicrob Agents Chemother*.
382 2015;59(6):3018–30.
- 383 12. Plowe C V. Malaria chemoprevention and drug resistance: a review of the literature
384 and policy implications. Vol. 21, *Malaria Journal*. BioMed Central Ltd; 2022.
- 385 13. Batwala V, Magnussen P, Nuwaha F. Challenges to implementation of artemisinin
386 combination therapy policy in Uganda. *Int Health*. 2010 Dec;2(4):262–8.

- 387 14. Ocan M, Nakalembe L, Otike C, Omali D, Buzibye A, Nsohya S. Pharmacopeial
388 quality of artemether–lumefantrine anti-malarial agents in Uganda. *Malar J*.
389 2023;22(1):1–11.
- 390 15. Ocan M, Obuku EA, Bwanga F, Akena D, Richard S, Ogwal-Okeng J, et al.
391 Household antimicrobial self-medication: a systematic review and meta-analysis of the
392 burden, risk factors and outcomes in developing countries. *BMC Public Health*.
393 2015;15:1–11.
- 394 16. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A
395 molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature*.
396 2014;505(7481):50–5.
- 397 17. Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al.
398 Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium*
399 *falciparum* kelch13 R561H mutant parasites in Rwanda. *Nat Med*. 2020;26(10):1602–
400 8.
- 401 18. Uwimana A, Umulisa N, Venkatesan M, Savigel SS, Zhou Z, Munyaneza T, et al.
402 Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed
403 parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic
404 efficacy study. *Lancet Infect Dis*. 2021 Aug 1;21(8):1120–8.
- 405 19. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al.
406 Evidence of artemisinin-resistant malaria in Africa. *New England Journal of Medicine*.
407 2021;385(13):1163–71.
- 408 20. Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing
409 prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin
410 resistance across Uganda. *J Infect Dis*. 2021;223(6):985–94.

- 411 21. Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, et al.
412 Decreased susceptibility of *Plasmodium falciparum* to both dihydroartemisinin and
413 lumefantrine in northern Uganda. *Nat Commun.* 2022;13(1).
- 414 22. Kanya MR, Bakyaitya NN, Talisuna AO, Were WM, Staedke SG. Increasing
415 antimalarial drug resistance in Uganda and revision of the national drug policy. Vol. 7,
416 *Tropical Medicine and International Health.* 2002. p. 1031–41.
- 417 23. Sendagire H, Kaddumukasa M, Ndagire D, Aguttu C, Nassejje M, Pettersson M, et al.
418 Rapid increase in resistance of *Plasmodium falciparum* to chloroquine-Fansidar in
419 Uganda and the potential of amodiaquine-Fansidar as a better alternative. *Acta Trop.*
420 2005 Sep;95(3):172–82.
- 421 24. Dowhaniuk N. Exploring country-wide equitable government health care facility
422 access in Uganda. *Int J Equity Health.* 2021 Dec 1;20(1).
- 423 25. Rahimi A, Kassam R, Dang Z, Sekiwunga R. Challenges with accessing health care
424 for young children presumed to have malaria in the rural district of Butaleja, Uganda:
425 A qualitative study. *Pharm Pract (Granada).* 2019;17(4).
- 426 26. National Malaria Control Division (NMCD) & Uganda Bureau of Statistics (UBOS).
427 2018-19 Uganda Malaria Indicator Survey (UMIS) Atlas of Key Indicators. 2018;
428 Available from: <https://dhsprogram.com/pubs/pdf/ATR21/ATR21.pdf>
- 429 27. Kamau E, Tolbert LDS, Kortepeter L, Pratt M, Nyakoe N, Muringo L, et al.
430 Development of a highly sensitive genus-specific quantitative reverse transcriptase
431 real-time PCR assay for detection and quantitation of *plasmodium* by amplifying RNA
432 and DNA of the 18S rRNA genes. *J Clin Microbiol.* 2011 Aug;49(8):2946–53.
- 433 28. Tadele G, Jaiteh FK, Oboh M, Oriero E, Dugassa S, Amambua-Ngwa A, et al.
434 Persistence of Residual Submicroscopic *P. falciparum* Parasitemia following

- 435 Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia.
436 Antimicrob Agents Chemother. 2022 Sep 1;66(9).
- 437 29. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT
438 method. Nat Protoc. 2008 May;3(6):1101–8.
- 439 30. Betson M, Sousa-Figueiredo JC, Atuhaire A, Arinaitwe M, Adriko M, Mwesigwa G, et
440 al. Detection of persistent Plasmodium spp. infections in Ugandan children after
441 artemether-lumefantrine treatment. Parasitology. 2014 Dec 12;141(14):1880–90.
- 442 31. Mhamilawa LE, Ngasala B, Morris U, Kitabi EN, Barnes R, Soe AP, et al. Parasite
443 clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an
444 extended 6-day treatment of artemether-lumefantrine and a single low-dose
445 primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district,
446 Tanzania: A randomized controlled trial. Malar J. 2020;19(1).
- 447 32. Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larsson E, Malmberg M, et al. Prevalence of
448 and Risk Factors Associated with Polymerase Chain Reaction-Determined
449 Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether–
450 Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania.
451 American Journal of Tropical Medicine and Hygiene. 2019;100(5).
- 452 33. Vreden SGS, Jitan JK, Bansie RD, Adhin MR. Evidence of an increased incidence of
453 day 3 parasitaemia in Suriname: An indicator of the emerging resistance of
454 Plasmodium falciparum to artemether. Mem Inst Oswaldo Cruz. 2013;108(8):968–73.
- 455 34. Health Organization W. Artemisinin resistance and artemisinin-based combination
456 therapy efficacy (Status report -- August 2018) [Internet]. 2018 [cited 2024 Apr 5].
457 Available from: [http://apps.who.int/iris/bitstream/handle/10665/274362/WHO-](http://apps.who.int/iris/bitstream/handle/10665/274362/WHO-CDS-GMP-2018.18-eng.pdf?sequence=1&isAllowed=y)
458 [CDS-GMP-2018.18- eng.pdf?sequence=1&isAllowed=y](http://apps.who.int/iris/bitstream/handle/10665/274362/WHO-CDS-GMP-2018.18-eng.pdf?sequence=1&isAllowed=y)

- 459 35. Ahorhorlu SY, Quashie N Ben, Jensen RW, Kudzi W, Nartey ET, Duah-Quashie NO,
460 et al. Assessment of artemisinin tolerance in *Plasmodium falciparum* clinical isolates
461 in children with uncomplicated malaria in Ghana. *Malar J.* 2023;22(1).
- 462 36. Wu Y, Soe MT, Aung PL, Zhao L, Zeng W, Menezes L, et al. Efficacy of artemether-
463 lumefantrine for treating uncomplicated *Plasmodium falciparum* cases and molecular
464 surveillance of drug resistance genes in Western Myanmar. *Malar J.* 2020;19(1).
- 465 37. Maniga JN, Akinola SA, Odoki M, Odda J, Adebayo IA. Limited polymorphism in
466 *Plasmodium falciparum* artemisinin resistance kelch13-propeller gene among clinical
467 isolates from bushenyi district, Uganda. *Infect Drug Resist.* 2021;14:5153–63.
- 468 38. Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative
469 efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the
470 treatment of uncomplicated malaria in Ugandan children. *Journal of Infectious*
471 *Diseases.* 2019 Mar 15;219(7):1112–20.
- 472 39. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al.
473 Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for
474 the treatment of uncomplicated *Plasmodium falciparum* malaria and prevalence of
475 molecular markers associated with artemisinin and partner drug resistance in Uganda.
476 *Malar J.* 2021 Dec 1;20(1).
- 477 40. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al. Supervised
478 versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute,
479 uncomplicated *Plasmodium falciparum* malaria in Mbarara, Uganda: a randomised
480 trial. *The Lancet.* 2005;365(9469):1467–73.
- 481 41. Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, et al. Residual
482 *Plasmodium falciparum* parasitemia in Kenyan children after artemisinin-combination

- 483 therapy is associated with increased transmission to mosquitoes and parasite
484 recurrence. *Journal of Infectious Diseases*. 2013 Dec 15;208(12):2017–24.
- 485 42. Asua V, Vinden J, Conrad MD, Legac J, Kigozi SP, Kanya MR, et al. Changing
486 molecular markers of antimalarial drug sensitivity across Uganda. *Antimicrob Agents*
487 *Chemother*. 2019;63(3).
- 488 43. Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V, et al.
489 Changing antimalarial drug resistance patterns identified by surveillance at three sites
490 in Uganda. *Journal of Infectious Diseases*. 2017 Feb 15;215(4):631–5.
- 491 44. Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, et al. Evolution of
492 Partial Resistance to Artemisinins in Malaria Parasites in Uganda. *New England*
493 *Journal of Medicine*. 2023 Aug 24;389(8):722–32.
- 494 45. Stokes BH, Ward KE, Fidock DA. Evidence of artemisinin-resistant malaria in Africa.
495 *N Engl J Med*. 2022;386(14):1385.
- 496 46. Ghanchi NK, Qurashi B, Raees H, Beg MA. Molecular surveillance of drug resistance:
497 *Plasmodium falciparum* artemisinin resistance single nucleotide polymorphisms in
498 Kelch protein propeller (K13) domain from Southern Pakistan. *Malar J*. 2021 Dec
499 1;20(1).
- 500 47. Maïga-Ascofaré O, May J. Is the A578S single-nucleotide polymorphism in K13-
501 propeller a marker of emerging resistance to artemisinin among *plasmodium*
502 *falciparum* in Africa? Vol. 213, *Journal of Infectious Diseases*. Oxford University
503 Press; 2016. p. 165–6.
- 504 48. Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of
505 the frequencies of *Plasmodium falciparum* Kelch 13 artemisinin resistance mutations
506 in Africa. Vol. 16, *International Journal for Parasitology: Drugs and Drug Resistance*.
507 2021.

- 508 49. Ocan M, Ashaba FK, Mwesigwa S, Edgar K, Kanya MR, Nsohya SL. Prevalence of
509 arps10, fd, pfmdr-2, pfcr1 and pfkelch13 gene mutations in Plasmodium falciparum
510 parasite population in Uganda. PLoS One. 2022 May 1;17(5 May).
- 511 50. Hawkes M, Conroy AL, Opoka RO, Namasopo S, Zhong K, Conrad Liles W, et al.
512 Slow clearance of Plasmodium falciparum in severe pediatric malaria, Uganda, 2011–
513 2013. Emerg Infect Dis. 2015;21(7):1237–9.
- 514 51. Ménard D, Khim N, Beghain J, Adegnikaa AA, Shafiul-Alam M, Amodu O, et al. A
515 Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms . New
516 England Journal of Medicine. 2016 Jun 23;374(25):2453–64.
- 517 52. Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of
518 K13 mutations in Plasmodium falciparum persisting after artemisinin combination
519 therapy treatment of Kenyan children. Malar J. 2016 Jan 22;15(1).
- 520 53. Ocan M, Bwanga F, Okeng A, Katabazi F, Kigozi E, Kyobe S, et al. Prevalence of
521 K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated
522 from adult symptomatic patients in northern Uganda. BMC Infect Dis. 2016;16(1):1–9.
- 523 54. Straimer J, Gandhi P, Renner KC, Schmitt EK. High Prevalence of Plasmodium
524 falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance
525 After Treatment With Artemether-Lumefantrine. Journal of Infectious Diseases. 2022
526 Apr 15;225(8):1411–4.
- 527